Product details
Catalog number PB9093-APC
Price for PB9093-APC
Size / count 100 µg/Vial
Boster Bio Anti-CD3 epsilon/CD3E Antibody Picoband® catalog # PB9093. Tested in IF, IHC, IHC-F, ICC, WB applications. This antibody reacts with Chicken, Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
The catalog number for Anti-CD3 epsilon/CD3E Antibody Picoband® (APC Conjugate) is PB9093-APC.
Anti-CD3 epsilon/CD3E Antibody Picoband® (APC Conjugate) is available in the following size(s): 100 µg/Vial.
Anti-CD3 epsilon/CD3E Antibody Picoband® (APC Conjugate) is currently made to order / not held in immediate stock. Contact us for lead time.
The safety data sheet for Anti-CD3 epsilon/CD3E Antibody Picoband® (APC Conjugate) is available here: https://www.bosterbio.com/msds?sku=PB9093.
Boster Bio Anti-CD3 epsilon/CD3E Antibody Picoband® catalog # PB9093. Tested in IF, IHC, IHC-F, ICC, WB applications. This antibody reacts with Chicken, Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals
Shelf life and expiration dates vary by product and are shown on the product listing and label. Products used beyond their expiration date are not eligible for performance-related returns or refunds, so please check the lot number and expiry before use.
The expression system, such as E. coli, HEK293, or insect cells, is listed on the datasheet under production details, which can affect post-translational modifications relevant to your application.
As a consumer, you have a 14-day right of withdrawal from receipt under EU consumer protection law, submitted via our withdrawal/cancellation request form. Note this applies to unused, undamaged products, and doesn’t override the expiry/storage conditions on performance-based claims.